Figure S1. Expression levels of miRNA in hepatocytes from mice fed HFD or CD. Expression levels of (A) miR-122-5p, (B) miR-129-5p, (C) miR-135a-3p and (D) miR-504-3p were assessed in hepatocytes isolated from mice fed HFD or CD using reverse transcription-quantitative PCR (n=5/group). Data are presented as the mean ± SD. *P<0.05, **P<0.01. miR, microRNA; HFD, high-fat diet; CD, chow diet; NS, not significant.



Figure S2. Expression levels of screened miRs in serum from patients with NAFLD and healthy controls. Serum expression levels of (A) miR-122-5p, (B) miR-129-5p, (C) miR-135a-3p and (D) miR-504-3p were assessed in patients with NAFLD (n=10) and healthy controls (n=10) using reverse transcription-quantitative PCR. Data are presented as the mean ± SD. *P<0.05, ***P<0.001. miR, microRNA; NAFLD, non-alcoholic fatty liver disease; NS, not significant.



Table SI. NAS of HFD mice and controls.

Parameter	CD (n=5)	HFD (n=5)
Steatosis	0.00±0.00	2.80±0.45
Hepatocyte hypertrophy	0.00±0.00	0.20±0.44
Inflammation	0.20±0.44	1.00±0.00
Fibrosis	0.00±0.00	0.20±0.44
NAS	0.20±0.44	4.20±0.84

NAS grading steatosis, ballooning (hepatocyte hypertrophy), inflammation and fibrosis. Data are presented as the mean ± SD. NAS, non-alcoholic steatohepatitis activity score; HFD, high-fat diet; CD, chow diet.